Tiny Jaarsma Linköping University No conflict of interest

Similar documents
Akash Ghai MD, FACC February 27, No Disclosures

Pearls in Acute Heart Failure Management

Cardiorenal and Renocardiac Syndrome

The Art and Science of Diuretic therapy

Estimated 5.7 million Americans with HF. 915, 000 new HF cases annually, HF incidence approaches

Sodium and HF: Myth?

Hyponatremia in Heart Failure: why it is important and what should we do about it?

Treating HF Patients with ARNI s Why, When and How?

Updates in Congestive Heart Failure

Disclosure of Relationships

Patient details GP details Specialist details Name GP Name Dr Specialist Name Dr R. Horton

Entresto Development of sacubitril/valsartan (LCZ696) for the treatment of heart failure with reduced ejection fraction

Drugs acting on the reninangiotensin-aldosterone

LXIV: DRUGS: 4. RAS BLOCKADE

Advanced Care for Decompensated Heart Failure

Role of Minerals in Hypertension

The Cardiorenal Syndrome in Heart Failure

Heart Failure with Reduced EF. Dino Recchia, MD, FACC, FHFSA

Cardiorenal Syndrome

The Failing Heart in Primary Care

Summary/Key Points Introduction

Copyright 2011, 2007 by Mosby, Inc., an affiliate of Elsevier Inc. Normal Cardiac Anatomy

Blood Pressure Regulation 2. Faisal I. Mohammed, MD,PhD

Blood Pressure Regulation 2. Faisal I. Mohammed, MD,PhD

Over- and underfill: not all nephrotic states are equal. Detlef Bockenhauer

BIOL 2402 Fluid/Electrolyte Regulation

Therapeutic Targets and Interventions

Combination of renin-angiotensinaldosterone. how to choose?

State-of-the-Art: Treatment of Renal Dysfunction in Heart Failure. W. H. Wilson Tang, MD Cleveland Clinic, U.S.A.

To see a description of the Academy Recommendation Rating Scheme (Strong, Fair, Weak, Consensus, Insufficient Evidence) visit the EAL.

ANGIOTENSIN RECEPTOR-NEPRILYSIN INHIBITORS IN HEART FAILURE FROM CHD

WHAT S NEW IN HEART FAILURE

Heart Failure Guidelines For your Daily Practice

From Sodium Retention to Therapy for Refractory Ascites The Role for New Drugs. Florence Wong University of Toronto. Falk Symposium October 14, 2007

HeFSSA Practitioners Program 2017 Theme The Patient Journey: Feel Good and Live Long. Case Study 2

Antialdosterone treatment in heart failure

Optimizing CHF Therapy: The Role of Digoxin, Diuretics, and Aldosterone Antagonists

Cardiorenal Syndrome Prof. Dr. Bülent ALTUN Hacettepe University Faculty of Medicine Department of Internal Medicine Division of Nephrology

Blood Pressure Fox Chapter 14 part 2

Heart Failure: Combination Treatment Strategies

Aldosterone Antagonism in Heart Failure: Now for all Patients?

UNDERSTANDING BLOOD TESTS

Case Study: Chronic Kidney Disease


Metabolic Syndrome and Chronic Kidney Disease

Doppler ultrasound, see Ultrasonography. Magnetic resonance imaging (MRI), kidney oxygenation assessment 75

Overcoming the Cardiorenal Syndrome

Heart Failure Update John Coyle, M.D.

Chronic Kidney Disease. Basics of CKD Terms Diagnosis Management

Biomarkers, the Kidney and the Heart: Acute Kidney Injury

Virtual Mentor American Medical Association Journal of Ethics April 2007, Volume 9, Number 4:

Prevalence of Sodium and Fluid Restriction Recommendations for Patients with Pulmonary Hypertension

Heart Failure Clinician Guide JANUARY 2016

Heart Failure Medical and Surgical Treatment

Renal Denervation. Henry Krum MBBS PhD FRACP. Centre of Cardiovascular Research & Monash University/Alfred Hospital;

HEART FAILURE SUMMARY. and is associated with significant morbidity and mortality. the cornerstone of heart failure treatment.

Mechanism: 1- waterretention from the last part of the nephron which increases blood volume, venous return EDV, stroke volume and cardiac output.

UPDATES IN MANAGEMENT OF HF

Genetic and physiological markers of salt sensitivity and its effects on salt taste perception and intake

Heart Failure. Subjective SOB (shortness of breath) Peripheral edema. Orthopnea (2-3 pillows) PND (paroxysmal nocturnal dyspnea)

Overview & Update on the Utilization of the Natriuretic Peptides in Heart Failure

Satish K Surabhi, MD.FACC,FSCAI,RPVI Medical Director, Cardiac Cath Labs AnMed Health Heart & Vascular Care

Heart Failure: Guideline-Directed Management and Therapy

Heart-failure or Kidney Failure?

HEART FAILURE PHARMACOLOGY. University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D

A high-sodium diet is associated with acute decompensated heart failure in ambulatory heart failure patients: a prospective follow-up study 1 3

Normal-sodium diet compared with low-sodium diet in compensated congestive heart failure: is sodium an old enemy or a new friend?

Nesiritide: Harmful or Harmless?

Heart Failure Pharmacotherapy An Update

Disclosures for Presenter

LCZ696 A First-in-Class Angiotensin Receptor Neprilysin Inhibitor

A. Study Purpose and Rationale Background

DECLARATION OF CONFLICT OF INTEREST

2017 Summer MAOFP Update

Clinical efficacy of ultrafiltration in the treatment of acute decompensated heart failure with diuretic resistance.

The Evidence for Populationwide Reduction in Sodium Intake: Why All the Fuss?

Year 2004 Paper two: Questions supplied by Megan 1

Paul M McKie, Alessandro Cataliotti, Guido Boerrigter, Horng C Chen, Fernando L Martin, and John C Burnett Jr

Pivotal Role of Renal Function in Acute Heart failure

What s new in heart failure management? Yonsei Cardiovascular Center Yonsei University College of Medicine

BODY FLUID. Outline. Functions of body fluid Water distribution in the body Maintenance of body fluid. Regulation of fluid homeostasis

ESC Guidelines for the Diagnosis and Treatment of Chronic Heart Failure

Disclosure Statement. Heart Failure: Refreshers and Updates. Objectives. CHF: Chronic Heart Failure. Definitions. Definitions 2/19/2018

Cardiorenal Syndrome

1/4/18. Heart Failure Guideline Review and Update. Disclosure. Pharmacist Objectives. Pharmacy Technician Objectives. What is Heart Failure?

Regulation of Body Fluids: Na + and Water Linda Costanzo, Ph.D.

Heart Failure with Preserved EF (HFPEF) Epidemiology and management

Heart Failure and Renal Disease Cardiorenal Syndrome

RAAS blocker + B Blocker Troubleshooting

Sacubitril/Valsartan unter der Lupe Subgruppenanalysen, real world data,

keyword: diuretics Drug monitoring Monitoring diuretics in primary care 2 March 2009 best tests

Beyond ACE-inhibitors for Heart Failure. Jacob Townsend, MD NCVH Birmingham 2015

Heart Failure. Acute. Plasma [NE] (pg/ml) 24 Hours. Chronic

BIPN100 F15 Human Physiology (Kristan) Lecture 18: Endocrine control of renal function. p. 1

New Trials. Iain Squire. Professor of Cardiovascular Medicine University of Leicester. Chair, BSH

Medical Treatment for acute Decompensated Heart Failure. Vlasis Ninios Cardiologist St. Luke s s Hospital Thessaloniki 2011

Hyponatremia as a Cardiovascular Biomarker

CASE STUDIES IN ADVANCED HEART FAILURE

Acutely decompensated heart failure (HF) is one of the most

DISCLOSURES OUTLINE OUTLINE 9/29/2014 ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE

Transcription:

Detrimental effects of sodium in heart failure - Tiny Jaarsma Linköping University No conflict of interest

Sodium restriction in Heart Failure Why? Prevention of heart failure Blood pressure treatment trials of 2 5 years have demonstrated that lowering BP could reduce heart failure by over 50%. He, et al., EHJ 2011; Chobanian et al., Hypertension 2003

Sodium and heart failure He F J et al. Eur Heart J 2011;32:3073-3080

Sodium restriction in Heart Failure Why? Prevention of heart failure Blood pressure treatment trials of 2 5 years have demonstrated that lowering BP could reduce heart failure by over 50%. Prevention of deterioration and complications Improve outcomes He, et al., EHJ 2011; Chobanian et al., Hypertension 2003

Sodium restriction: beneficial or harmful? beneficial harmful

Arterial underfilling with resultant neurohumoral activation and renal sodium and water retention. Bansal S et al. Circ Heart Fail 2009;2:370-376 Copyright American Heart Association

Effects of sodium intake in heart failure: low-sodium intake may have varied effect on heart failure. Gupta D et al. Circulation 2012;126:479-485 Copyright American Heart Association

Sodium restriction? beneficial

Sodium restriction beneficial? Arcand et al., Journal of Clinical Nutrition 2011

Sodium restriction beneficial? 123 medically stable patients with systolic HF Multiple day food records at 2 time points Endpoints: HF hospitalization / HF ER visit, all-cause hospitalization and death or transplantation. 3 year follow-up Sodium: <1.9 g Na/d (n = 41) 2.0 2.7 Na/d (n = 41) >2.8 Na/d (n = 41) Arcand et al., Journal of Clinical Nutrition 2011

Arcand et al., Journal of Clinical Nutrition 2011

Sodium restriction beneficial? Heart failure patients who consumed a high sodium diet (2.8 g Na/d), compared with patients who consumed lower amounts of dietary sodium, had a higher incidence of early advanced HF. Patients who consumed a high-sodium diet had a 2.5-fold increased risk of advanced HF and an elevated risk of all-cause hospitalization and mortality when adjusted for covariates Arcand et al., Journal of Clinical Nutrition 2011

Sodium restriction beneficial? 302 HF patients 24-hour urine sodium to indicate sodium intake Endpoints: Event-free survival 1 year follow-up Sodium: >3g UNa and < 3 f UNa Lennie et al., Journal of Cardiac Failure 2011

24-hour Urinary Sodium Excretion Lennie et al., Journal of Cardiac Failure 2011 15

Lennie et al., Journal of Cardiac Failure 2011

Lennie et al., Journal of Cardiac Failure 2011

Sodium restriction? harmful

Sodium restriction harmful?

Sodium restriction harmful? 232 compensated HF patients Furosemide 250 500 mg + 1000 ml fluid restriction 180 days of follow-up. Randomized into two groups: group 1 (n= 118) normal sodium diet (120 mmol of sodium = 2.8 g) group 2 (n= 114) low-sodium diet (80 mmol of sodium =1.8 g) Endpoints: worsening HF (primary end point). Readmissions and mortality, plasma BNP, aldosterone levels, and PRA (plasma renin activity) Paterna et al., 2008

Sodium restriction harmful? At 180 days,: Low (1.8 g) sodium diet group had higher B-type natriuretic peptide levels higher aldosterone levels experienced a 44% increase in plasma rennin activity from baseline At 12-month Low (1.8 g) sodium diet group had similar neurohormonal activation higher rates of hospital admissions or death higher levels of the proinflammatory cytokines Paterna et al., 2008, Parrinello 2009

normal-sodium diet improves outcome, and sodium depletion has detrimental renal and neurohormonal effects with worse clinical outcome in compensated HF patients. Further studies are required to determine if this is due to a high dose of diuretic or the low-sodium diet. NB strong fluid restriction, low betablockers Paterna et al., 2008

Paterna et al., 2009

Paterna et al., 2009

Paterna et al., 2009

Group A showed the best results, with a significant reduction (p <0.001) in readmissions, BNP, aldosterone, and plasma renin activity compared with the other groups during follow-up (p <0.001). Paterna et al., 2009

Paterna et al., 2009

Salt-fluids-diuretics?

Sodium restriction: beneficial or harmful?

Physiological and Neurohormonal Responses Inconsistent with regard to cardiac index Natriuretic peptide levels were affected inconsistently among studies; Levels of neurohormones increased with dietary sodium restriction regardless of degree of restriction Diuresis, Electrolyte, and Renal Responses low dietary sodium intake -> increase in blood urea nitrogen and creatinine, whereas moderate-to-high sodium intake was related to decreased creatinine HF or non-hf readmission rates and mortality rates Inconsistent in several studies. Mortality rate was lower in the moderate-to-high sodium group in 3 studies in comparison with lowsodium diet. Gupta et al., 2012 32

HF patients want more salt? Angiotensin II (ANG II) the major effector peptide of the RAAS acts on and in the brain to stimulate both thirst and salt appetite Does circulating ANG II and/or aldosterone act to enhance the motivation to consume excess salt under conditions such as HF? HF patients may actually have an enhanced avidity or preference for salty tastes that may drive excess salt consumption and low compliance with low sodium diets.. De Souza, 2012

Taste? Method Case-control prospective study including 38 patients with clinically stable HF NYHA II or III 25 healthy volunteers Bean soup with varying salt content De Souza, 2012

1. Questionnaire on food preferences 2. Preference test: salt concentrations (0.58, 0.82, and 1.16 g/100 g) of bean soup were presented to the subjects De Souza, 2012

HF patients want more salt? HF outpatients as compared to healthy volunteers had an increased preference for salt as indicated by their preferred concentration of salt contained in a bean soup preparation. HF patients also actually disliked soup with a low concentration of salt. It is concluded that medicated, compensated patients under chronic treatment for HF have an increased preference for salt. De Souza, 2012

37

Conclusion We do know that very high sodium intake is not optimal, but we do not know (1) what the lower safest and most efficacious range is and (2) if that range would be applicable to all patients, or needs to be individualized Gupta et al., 2012

What do the new guidelines say? (2012) McMurray et al. EJHF & EHJ 2012 1

40